** Cancer therapy developer Kronos Bio's shares rise 4% to 90 cents premarket
** KRON to lay off about 83% of its employees by year-end
** CEO Norbert Bischofberger has stepped down after nearly six years in the role - KRON
** KRON appoints chief financial officer Deborah Knobelman as interim CEO
** As of March 11, KRON had 62 full-time employees and one part-time employee - SEC filing
** KRON had announced ~21% reduction in its workforce earlier this year
** As of last close, stock has fallen ~31% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。